Teva Pharmaceuticals Discontinues Phase 2 Emrusolmin Study for Multiple System Atrophy
Teva Pharmaceutical Industries (TEVA) has announced the discontinuation of its Phase 2 TOPAS-MSA clinical study, which was evaluating the efficacy of emrusolmin (TEV-‘286) in treating adults with multiple system atrophy (MSA). The decision follows a formal recommendation from an independent data monitoring committee. The move represents a setback in Teva's neurological pipeline as the company pivots its research focus. While the specific reasons for the committee's recommendation were not detailed, the cessation of this clinical trial indicates that the drug failed to meet necessary efficacy or safety benchmarks required to proceed to further development stages.
Tickers: $TEVA
Topics: clinical trial discontinuation drug development multiple system atrophy
Read the full article at Seeking Alpha
Part of the story Teva discontinues Phase 2 study of Emrusolmin in multiple system atrophy (2 articles)